ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NUMD Nu Med Plus Inc (QB)

0.085
0.0181 (27.06%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nu Med Plus Inc (QB) USOTC:NUMD OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0181 27.06% 0.085 0.06 0.088 0.085 0.0645 0.07275 14,666 21:00:00

Current Report Filing (8-k)

21/03/2017 5:13pm

Edgar (US Regulatory)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549



FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


March 16, 2017

(Date of Report: Date of earliest event reported)



NU-MED PLUS, INC.

(Exact name of registrant as specified in its charter)


Utah

000-54808

45-3672530

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)


455 East 500 South, Suite 203, Salt Lake City, Utah 84111

 (Address of principal executive office) (Zip Code)


Registrant's telephone number, including area code: (801) 746-3570



__________________________________________

 (Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).





SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS


This document contains forward-looking statements, which reflect our views with respect to future events and financial performance. These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from such statements. These forward-looking statements are identified by, among other things, the words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets” and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Important factors that may cause actual results to differ from those projected include the risk factors specified below.


Item 8.01 Other Events.


On March 16, 2017 the Company filed a complaint against a former Consultant and Officer related to consulting agreements and the return of unearned shares.  The Company is requesting the return of such unearned shares.


The former Officer and Consultant has filed a claim against the Company and its President relating to these shares.


The Company will vigorously prosecute and defend there claim which requests the return of unearned shares.


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.


NU-MED PLUS, INC.



By: /s/ Jeffrey L. Robins

Date: March 20, 2017

      Jeffrey L. Robins, CEO




1 Year Nu Med Plus (QB) Chart

1 Year Nu Med Plus (QB) Chart

1 Month Nu Med Plus (QB) Chart

1 Month Nu Med Plus (QB) Chart

Your Recent History

Delayed Upgrade Clock